ELI LILLY AND COMPANY Operating Expenses
ELI LILLY AND COMPANY (LLY) reported Operating Expenses of $3.28 billion for the 3-month period ending 2019-12-31, per its 10-K filed 2020-02-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-02-19
- ELI LILLY AND COMPANY operating expenses for the quarter ending 2019-12-31 was $3.28B, a 6.29% increase year-over-year.
- ELI LILLY AND COMPANY operating expenses for the quarter ending 2019-09-30 was $2.79B, a 2.01% increase year-over-year.
- ELI LILLY AND COMPANY operating expenses for the quarter ending 2019-06-30 was $2.99B, a 8.41% increase year-over-year.
- ELI LILLY AND COMPANY operating expenses for the quarter ending 2019-03-31 was $2.75B, a 12.32% increase year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $3.28B 10-K · filed 2020-02-19 | $6.07B derived: sum of 2 quarters · filed 2020-02-19 | $9.06B derived: sum of 3 quarters · filed 2020-02-19 | $11.81B derived: sum of 4 quarters · filed 2020-02-19 | |
| 2019-09-30 | $2.79B 10-K · filed 2020-02-19 | $5.78B derived: sum of 2 quarters · filed 2020-02-19 | $8.53B derived: sum of 3 quarters · filed 2020-02-19 | $11.61B derived: sum of 4 quarters · filed 2020-02-19 | |
| 2019-06-30 | $2.99B 10-K · filed 2020-02-19 | $5.74B derived: sum of 2 quarters · filed 2020-02-19 | $8.82B derived: sum of 3 quarters · filed 2020-02-19 | $11.56B derived: sum of 4 quarters · filed 2020-02-19 | |
| 2019-03-31 | $2.75B 10-K · filed 2020-02-19 | $5.83B derived: sum of 2 quarters · filed 2020-02-19 | $8.57B derived: sum of 3 quarters · filed 2020-02-19 | $11.33B derived: sum of 4 quarters · filed 2020-02-19 | |
| 2018-12-31 | $3.09B 10-K · filed 2020-02-19 | $3.32B 10-K · filed 2019-02-19 | $5.82B derived: sum of 2 quarters · filed 2020-02-19 | $8.58B derived: sum of 3 quarters · filed 2020-02-19 | $11.03B derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-09-30 | $2.74B 10-K · filed 2020-02-19 | $2.96B 10-K · filed 2019-02-19 | $5.49B derived: sum of 2 quarters · filed 2020-02-19 | $7.94B derived: sum of 3 quarters · filed 2020-02-19 | $10.99B derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $2.76B 10-K · filed 2020-02-19 | $2.99B 10-K · filed 2019-02-19 | $5.20B derived: sum of 2 quarters · filed 2020-02-19 | $8.26B derived: sum of 3 quarters · filed 2020-02-19 | $10.94B derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $2.45B 10-K · filed 2020-02-19 | $2.68B 10-K · filed 2019-02-19 | $5.50B derived: sum of 2 quarters · filed 2020-02-19 | $8.18B derived: sum of 3 quarters · filed 2020-02-19 | $10.94B derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $3.05B 8-K · filed 2019-10-24 | $3.25B 10-K · filed 2018-02-20 | $5.73B derived: sum of 2 quarters · filed 2019-10-24 | $8.50B derived: sum of 3 quarters · filed 2019-10-24 | $11.08B derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-09-30 | $2.68B 8-K · filed 2019-10-24 | $2.87B 10-K · filed 2018-02-20 | $5.44B derived: sum of 2 quarters · filed 2019-10-24 | $8.02B derived: sum of 3 quarters · filed 2019-10-24 | $11.27B derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-06-30 | $2.76B 8-K · filed 2019-10-24 | $2.96B 10-K · filed 2018-02-20 | $5.35B derived: sum of 2 quarters · filed 2019-10-24 | $8.59B derived: sum of 3 quarters · filed 2019-10-24 | $11.39B derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-03-31 | $2.58B 8-K · filed 2019-10-24 | $2.78B 10-K · filed 2018-02-20 | $5.82B derived: sum of 2 quarters · filed 2019-10-24 | $8.63B derived: sum of 3 quarters · filed 2019-10-24 | $11.58B derived: sum of 4 quarters · filed 2019-10-24 |
| 2016-12-31 | $3.24B 10-K · filed 2018-02-20 | $6.04B derived: sum of 2 quarters · filed 2018-02-20 | $9.00B derived: sum of 3 quarters · filed 2018-02-20 | $11.70B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-09-30 | $2.80B 10-K · filed 2018-02-20 | $5.76B derived: sum of 2 quarters · filed 2018-02-20 | $8.46B derived: sum of 3 quarters · filed 2018-02-20 | $11.70B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-06-30 | $2.96B 10-K · filed 2018-02-20 | $5.65B derived: sum of 2 quarters · filed 2018-02-20 | $8.90B derived: sum of 3 quarters · filed 2018-02-20 | $11.62B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-03-31 | $2.69B 10-K · filed 2018-02-20 | $5.94B derived: sum of 2 quarters · filed 2018-02-20 | $8.66B derived: sum of 3 quarters · filed 2018-02-20 | $11.46B derived: sum of 4 quarters · filed 2018-02-20 | |
| 2015-12-31 | $3.24B 10-K · filed 2017-02-21 | $5.96B derived: sum of 2 quarters · filed 2017-02-21 | $8.77B derived: sum of 3 quarters · filed 2017-02-21 | $11.33B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-09-30 | $2.72B 10-K · filed 2017-02-21 | $5.52B derived: sum of 2 quarters · filed 2017-02-21 | $8.09B derived: sum of 3 quarters · filed 2017-02-21 | $11.07B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-06-30 | $2.80B 10-K · filed 2017-02-21 | $5.37B derived: sum of 2 quarters · filed 2017-02-21 | $8.35B derived: sum of 3 quarters · filed 2017-02-21 | $11.27B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | $2.56B 10-K · filed 2017-02-21 | $5.55B derived: sum of 2 quarters · filed 2017-02-21 | $8.46B derived: sum of 3 quarters · filed 2017-02-21 | $11.32B derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $2.99B 10-K · filed 2016-02-19 | $5.90B derived: sum of 2 quarters · filed 2016-02-19 | $8.76B derived: sum of 3 quarters · filed 2016-02-19 | $11.35B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-09-30 | $2.92B 10-K · filed 2016-02-19 | $5.77B derived: sum of 2 quarters · filed 2016-02-19 | $8.37B derived: sum of 3 quarters · filed 2016-02-19 | $11.80B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $2.86B 10-K · filed 2016-02-19 | $5.45B derived: sum of 2 quarters · filed 2016-02-19 | $8.88B derived: sum of 3 quarters · filed 2016-02-19 | $11.91B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $2.59B 10-K · filed 2016-02-19 | $6.02B derived: sum of 2 quarters · filed 2016-02-19 | $9.05B derived: sum of 3 quarters · filed 2016-02-19 | $12.25B derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $3.43B 10-K · filed 2015-02-19 | $6.46B derived: sum of 2 quarters · filed 2015-02-19 | $9.66B derived: sum of 3 quarters · filed 2015-02-19 | $12.66B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-09-30 | $3.03B 10-K · filed 2015-02-19 | $6.23B derived: sum of 2 quarters · filed 2015-02-19 | $9.23B derived: sum of 3 quarters · filed 2015-02-19 | $12.67B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-06-30 | $3.20B 10-K · filed 2015-02-19 | $6.20B derived: sum of 2 quarters · filed 2015-02-19 | $9.64B derived: sum of 3 quarters · filed 2015-02-19 | $12.74B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-03-31 | $3.00B 10-K · filed 2015-02-19 | $6.44B derived: sum of 2 quarters · filed 2015-02-19 | $9.54B derived: sum of 3 quarters · filed 2015-02-19 | $12.79B derived: sum of 4 quarters · filed 2015-02-19 | |
| 2012-12-31 | $3.44B 10-K · filed 2014-02-19 | $6.54B derived: sum of 2 quarters · filed 2014-02-19 | $9.79B derived: sum of 3 quarters · filed 2014-02-19 | $12.79B derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-09-30 | $3.10B 10-K · filed 2014-02-19 | $6.35B derived: sum of 2 quarters · filed 2014-02-19 | $9.35B derived: sum of 3 quarters · filed 2014-02-19 | ||
| 2012-06-30 | $3.25B 10-K · filed 2014-02-19 | $6.25B derived: sum of 2 quarters · filed 2014-02-19 | |||
| 2012-03-31 | $3.00B 10-K · filed 2014-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |